CHST11

Across TCGA pan-cancer cohorts, CHST11 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CHST11 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CHST11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHST11 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, SCLC, and LGG are the cancer types where CHST11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.137	0.779	<.001	15	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →
LGG	OS	Median	All	0.134	0.799	<.001	10	view →
LUAD	OS	Median	All	0.250	0.788	.010	9	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
BLCA	DFS	Median	III,IV	1.000	0.429	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CHST11–LIHC (OS)

Open the LIHC breakdown →